/
ETON
$36.73+$1.03 (+2.89%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$977.9M
27M shares
52-week range
$13.51 – $36.95
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$30.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $959.0K | $39.0K | $21.8M | $21.3M | $31.6M | $39.0M | $80.0M |
| Cost of revenue | $63.0K | $453.0K | $286.0K | $2.6M | $6.9M | $10.6M | $15.6M | $37.2M |
| Gross profit | −$63.0K | $506.0K | −$247.0K | $19.2M | $14.3M | $21.1M | $23.4M | $42.7M |
| Gross margin | — | 52.8% | -633.3% | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| R&D | $5.6M | $11.6M | $14.1M | $6.2M | $4.0M | $3.3M | $3.3M | $7.8M |
| Operating income | −$10.3M | −$18.6M | −$27.1M | −$1.5M | −$8.3M | −$1.2M | −$2.6M | $72.0K |
| EBITDA | −$10.3M | −$18.2M | −$26.5M | −$1.5M | −$7.2M | $212.0K | −$657.0K | $4.3M |
| Net income | −$12.7M | −$18.3M | −$28.0M | −$2.0M | −$9.0M | −$936.0K | −$3.8M | −$4.6M |
| Net margin | — | -1910.3% | -71717.9% | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (diluted) | -1.99 | -1.02 | -1.33 | -0.08 | -0.36 | -0.04 | -0.15 | -0.17 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $113M | $0.80 | $0.73–$0.88 | 2 |
| 2027 | $183M | $1.90 | $1.82–$1.97 | 2 |
| 2028 | $244M | $3.02 | $2.18–$3.63 | 3 |
| 2029 | $347M | $5.01 | $4.89–$5.17 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Eton Pharmaceutcials, Inc. Common Stock
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
www.etonpharma.com- Employees
- 44
- IPO / List date
- Nov 14, 2018
- HQ
- DEER PARK, IL
Held by traders on TradeandTell
No one on the platform currently holds ETON.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 163,321 | $4.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ETON yet.
